{"ticker": {"uuid": "9a30a052-c427-4867-9f4c-5eaabc60614c", "symbol": "PTCT", "name": "PTC Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T16:22:27+00:00", "published_display": "19 Jul 2026 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNTUcwY1FLazBFeUZjY3dIN0JtNnBZcVdUNGhUX3RBTlBfYTJ2elBCeV9NRmw0d1lndzZWWlB6ZDMtYXlnY1FaZnRyYWRyYzVzQ3AzcF9Jd1dlU29xM3lyLWo4MlItVm4zNFc2dVVfM1JPY1FoRk52VWZVb2ZxcVpfcw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-19T14:58:42+00:00", "published_display": "19 Jul 2026 14:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026", "summary": "PTC Therapeutics, Inc. (PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results and provide business updates. Interested parties can access the live webcast via the Investors section of", "url": "https://www.tradingview.com/news/prnewswire:039ec3ab3880f:0-ptc-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-july-30-2026/", "source_name": "TradingView", "published_at": "2026-07-17T11:09:48", "published_display": "17 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics schedules second-quarter 2026 results webcast conference call", "summary": "PTC Therapeutics is scheduled to report its second-quarter 2026 financial results on July 30, 2026. A webcast conference call will be held on the same day at 4:30 p.m. ET, with a replay available for 30 days. This news brief was generated by Public Technologies using AI, based on", "url": "https://www.bitget.com/amp/news/detail/12560605510466", "source_name": "Bitget", "published_at": "2026-07-17T00:11:37", "published_display": "17 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 PTC Therapeutics Inc For: 16 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for PTC Therapeutics Inc for July 16, 2026. Form 4 filings are statements of changes in beneficial ownership of securities. The article briefly mentions other market news and includes market data and popular articles.", "url": "https://ca.investing.com/news/stock-market-news/form-4-ptc-therapeutics-inc-for-16-july-93CH-4738581", "source_name": "Investing.com Canada", "published_at": "2026-07-16T21:36:47", "published_display": "16 Jul 2026 21:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes", "summary": "PTC Therapeutics' CFO, Pierre Gravier, automatically sold 3,494 shares of common stock at $80.35 per share on July 14, 2026. This transaction was executed to fulfill tax withholding obligations tied to the vesting of 6,500 RSUs. After this sale, Gravier directly holds 83,986 shar", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-8f4a340316aa.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:20:47", "published_display": "16 Jul 2026 21:20", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PTC Therapeutics Sets July 30 Webcast for Business Update", "summary": "PTC Therapeutics (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results and provide a business and outlook update. Investors can access the live webcast and replay on the comp", "url": "https://www.stocktitan.net/news/PTCT/ptc-therapeutics-to-report-second-quarter-2026-financial-results-on-ds2l051yn3tn.html", "source_name": "Stock Titan", "published_at": "2026-07-16T12:09:47", "published_display": "16 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities", "summary": "Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on PTC Therapeutics (PTCT) with a $95.00 price target. This follows a similar Buy rating from J.P. Morgan, though RBC Capital maintained a Hold rating. The company recently reported a quarterly revenue of $27", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PTCT-Q/pressreleases/3313427/ptc-therapeutics-ptct-gets-a-buy-from-bank-of-america-securities/", "source_name": "The Globe and Mail", "published_at": "2026-07-16T11:09:47", "published_display": "16 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and a $124 price target for PTC Therapeutics (NASDAQ:PTCT), citing a strong launch for its PKU treatment, Sephience. The firm plans to engage management to discuss Sephience's global expansion, potential FDA dialogue for votop", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-ptc-therapeutics-stock-93CH-4793382", "source_name": "Investing.com", "published_at": "2026-07-15T12:40:46", "published_display": "15 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PTC THERAPEUTICS, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPUXoxZjRYZ0hqQWhvZEdEOFdNbnItZ0prTTUyU1lnejU2Zm11OEliLWZVa0lmVFdnV2JkemM2R2t0clRseGdxZ09Xbm5ib2ZNa0d5MTlYWHNYb2RLSlRCcXhuLTF3bDlVMTVXR2dYemVLcGR6bVlBekl6ZnZxT2pOQzUyVFdzTWVuSXNWVXlSbUNyZ2JzeFhENzB5OXZ1UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T19:14:52+00:00", "published_display": "14 Jul 2026 19:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders", "summary": "PTC Therapeutics reported strong Q1 2026 earnings, exceeding analyst expectations, with an improved outlook for its rare disease therapy Sephience. This positive news, despite pre-planned insider stock sales, supports the company's investment narrative and has led to analyst upgr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptct/ptc-therapeutics/news/what-ptc-therapeutics-ptcts-q1-beat-and-sephience-outlook-sh/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-14T20:14:36", "published_display": "14 Jul 2026 20:14", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Q1 2025 earnings summary", "summary": "PTC Therapeutics (PTCT) reported strong Q1 2025 results with a revenue of $1.18 billion, largely due to a $986.2 million Novartis upfront payment. The company achieved a net income of $866.6 million, a significant improvement from a net loss in Q1 2024, and ended the quarter with", "url": "https://quartr.com/events/ptc-therapeutics-inc-ptct-q1-2025_ofWxJ52K", "source_name": "Quartr", "published_at": "2026-07-14T10:14:36", "published_display": "14 Jul 2026 10:14", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) 2024 Wells Fargo Healthcare Conference Summary", "summary": "PTC Therapeutics (PTCT) presented at the 2024 Wells Fargo Healthcare Conference, highlighting strong financial performance with raised 2024 revenue guidance to $700\u2013$750 million and $1.09 billion in cash. The company provided updates on its pipeline, including three FDA applicati", "url": "https://quartr.com/events/ptc-therapeutics-inc-ptct-2024-wells-fargo-healthcare-conference_ofWxlfNE", "source_name": "Quartr", "published_at": "2026-07-14T09:40:17", "published_display": "14 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million", "summary": "", "url": "https://finance.yahoo.com/m/4b5bf0b2-8c95-309f-b0d5-9bb28d257380/what-this-ptc-therapeutics.html", "source_name": "Motley Fool", "published_at": "2026-07-13T23:48:52+00:00", "published_display": "13 Jul 2026 23:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 PTC Therapeutics Inc For: 13 July By Investing.com", "summary": "This article announces the filing of Form 4 for PTC Therapeutics Inc. on July 13. It is a very brief news item published by Investing.com, accompanied by a general market overview and links to other news and financial tools. The core content is the notification of the Form 4 fili", "url": "https://ng.investing.com/news/stock-market-news/form-4-ptc-therapeutics-inc-for-13-july-93CH-2597678", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:30:18", "published_display": "13 Jul 2026 22:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock", "summary": "Mary L. Smith, a director at PTC Therapeutics, sold 15,834 shares of common stock totaling approximately $1.43 million on July 9, 2026, after acquiring the same number of shares through stock option exercises. The sale occurred near the stock's 52-week high, following strong perf", "url": "https://www.investing.com/news/insider-trading-news/mary-l-smith-director-at-ptc-therapeutics-sells-143m-in-stock-93CH-4789468", "source_name": "Investing.com", "published_at": "2026-07-13T21:40:47", "published_display": "13 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) officer sells 2,464 shares after option exercise", "summary": "Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics (PTCT), exercised stock options to acquire 2,464 common shares at $46.54 and simultaneously sold these shares at a weighted average of $90.25 under a pre-arranged Rule 10b5-1 plan. Following these trans", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-e04210d5c28c.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:12:45", "published_display": "13 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) director trades 15,834 shares via option exercise and sale", "summary": "Mary L. Smith, a director at PTC Therapeutics (PTCT), exercised stock options for 15,834 shares at $42.95 each and subsequently sold all 15,834 shares at $90.00 each on July 9, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in Novembe", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-b5a89ab427f6.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:12:45", "published_display": "13 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PTC Therapeutics (PTCT) On Russell Index Inclusion And Pipeline Optimism With Fair Value In Focus", "summary": "PTC Therapeutics (PTCT) has gained investor attention due to its inclusion in three Russell 2000 Defensive indexes, two FDA New Drug Applications under review, and a potential Phase 3 Huntington's disease program. Despite reporting a loss of US$186.7 million, the company's fair v", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptct/ptc-therapeutics/news/ptc-therapeutics-ptct-on-russell-index-inclusion-and-pipelin", "source_name": "Simply Wall Street", "published_at": "2026-07-12T21:10:48", "published_display": "12 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Q2 2024 earnings summary", "summary": "PTC Therapeutics reported Q2 2024 total revenue of $187 million, with a 24% year-over-year decline in net product revenue due to lower Translarna and Emflaza sales, but a 44% increase in Evrysdi royalty revenue. The company significantly reduced its net loss to $99.2 million and ", "url": "https://quartr.com/events/ptc-therapeutics-inc-ptct-q2-2024_ofWxlcfM", "source_name": "Quartr", "published_at": "2026-07-11T20:40:21", "published_display": "11 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "This article summarizes PTC Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Key highlights include record Q1 product revenue driven by the SEPHIENCE launch, the broad R&D pipeline with ongoing clinical trials, and the significant mar", "url": "https://quartr.com/events/ptc-therapeutics-ptct-goldman-sachs-47th-annual-global-healthcare-conference-2026_ofWxvNWq", "source_name": "Quartr", "published_at": "2026-07-11T12:39:59", "published_display": "11 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNemZ2NmJKdjA1cHZ4OG91SEVlcWpMcGdPYWdBTWdlZ0Vfb0M2UGVXYmFmaWJRNVVRNnlTbG1jS0dTa3FER3h0QTFNQmE1Yy1VYmpzZFMzOHp6UGFaSVNUSi1UbzZhcUZjcFFfRU1wQ2NFN3RRRTFldkRURDdrVlVjaWduQUFwRHlPLUx2eExtQTZySnJyU3pJ?oc=5", "source_name": "Market source", "published_at": "2026-07-11T08:16:54+00:00", "published_display": "11 Jul 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PTC Therapeutics (PTCT) A Bargain Following Its Russell 2000 Defensive Index Additions?", "summary": "PTC Therapeutics (PTCT) has been added to three Russell 2000 Defensive indexes, which could influence investor interest. Despite strong recent share price performance and a common narrative suggesting the stock is 9.7% undervalued with a fair value of $93.93, valuation based on t", "url": "https://uk.finance.yahoo.com/news/ptc-therapeutics-ptct-bargain-following-231110876.html", "source_name": "Market source", "published_at": "2026-07-11T08:39:59", "published_display": "11 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics Drops 5.5% Amid Sector-Wide Selling", "summary": "PTC Therapeutics saw its share price drop by 5.5% on Friday, closing at $84.65, as part of a broader selloff in the biotechnology sector. The decline was largely attributed to sector-wide pressure rather than any company-specific news, with several peer companies experiencing sim", "url": "https://news.alphastreet.com/ptc-therapeutics-drops-5-5-amid-sector-wide-selling/amp/", "source_name": "AlphaStreet", "published_at": "2026-07-11T08:39:59", "published_display": "11 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTCT (NASDAQ: PTCT) affiliate sale notice \u2014 Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQNzR3QnYzZEhWUUY0dklNV3JvQjVtdXBXanlEelFyRVQwcDhBbDI3VGdTelRKYkliSFltczAxNjJQRTh5bmZBNnRuMWZMNWVSWmMxOU5hSGlYZC0xemU5TEwySlJTb0ttTFJ6RWtlWGNTd0VKdHdvelVZdExzZ2ZMN0NQUEw3ckRDc1ozRXVFbGNvZVI2RFJDYjc2RFhqQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:12:19+00:00", "published_display": "09 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 PTC Therapeutics Inc For: 8 July By Investing.com", "summary": "This article reports on a Form 4 filing for PTC Therapeutics Inc for July 8th. Form 4 filings disclose changes in beneficial ownership of company stock by insiders. The brief mention indicates an official financial transaction or holding update related to the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-ptc-therapeutics-inc-for-8-july-93CH-2591937", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T20:10:37", "published_display": "09 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the PTCT Inflection", "summary": "This article analyzes PTC Therapeutics Inc. (NASDAQ: PTCT), highlighting a strong sentiment across all horizons supporting an overweight bias. The analysis, generated by AI models, provides three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) ", "url": "https://news.stocktradersdaily.com/news_release/78/Responsive_Playbooks_and_the_PTCT_Inflection_070926125402_1783616042.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T13:19:04", "published_display": "09 Jul 2026 13:19", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics(PTCT.US) Officer Sells US$4.09 Million in Common Stock", "summary": "A PTC Therapeutics officer recently sold 150,000 shares of common stock for a total of $4.09 million. The transaction was disclosed through a Form 4 filing with the SEC.", "url": "https://www.moomoo.com/news/post/72670648/ptc-therapeutics-ptctus-officer-sells-us-4-09-million-in", "source_name": "Moomoo", "published_at": "2026-07-08T22:19:04", "published_display": "08 Jul 2026 22:19", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics\u2019 Mark Boulding, exec VP, sells $432,117 in stock", "summary": "Mark Elliott Boulding, Executive VP and CLO at PTC Therapeutics, Inc., sold 5,079 shares of common stock for $432,117 on July 6, 2026, under a pre-arranged trading plan. Concurrently, he acquired 5,079 shares by exercising stock options for $220,242, increasing his direct holding", "url": "https://www.investing.com/news/insider-trading-news/ptc-therapeutics-mark-boulding-exec-vp-sells-432117-in-stock-93CH-4782645", "source_name": "Investing.com", "published_at": "2026-07-08T22:10:06", "published_display": "08 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ptc therapeutics tech ops chief sells $4.1m in common stock", "summary": "PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold approximately $4.1 million in common stock and acquired $1.8 million worth of stock on July 6 and 7, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. The sales o", "url": "https://www.investing.com/news/insider-trading-news/ptc-therapeutics-tech-ops-chief-sells-41m-in-common-stock-93CH-4782646", "source_name": "Investing.com", "published_at": "2026-07-08T22:10:06", "published_display": "08 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) CLO sells shares under Rule 10b5-1 plan", "summary": "Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics (PTCT), reported selling 5,079 shares in open-market transactions and exercising options to acquire 5,039 shares on July 6, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted in Septe", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-2ccb8b73201d.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:10:06", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) officer sells shares after exercising options", "summary": "PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold 46,774 shares of common stock after exercising options. These transactions, executed on July 6-7, 2026, were performed under a pre-set Rule 10b5-1 trading plan. Almstead exercised options at prices ", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-942419ef17d8.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:10:05", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ptc-therapeutics-ptct-upgraded-strong-160004329.html", "source_name": "Zacks", "published_at": "2026-07-08T16:00:04+00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-capital-adjusts-ptc-therapeutics-112618060.html", "source_name": "MT Newswires", "published_at": "2026-07-07T11:26:18+00:00", "published_display": "07 Jul 2026 11:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTCT (NASDAQ) affiliate plans option exercise; director sold 10,522 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNdkFxelhYS3JzcTNTbERyb21MMS1QQ1huTDlDLVJnOVZoMlZ5RjdrV3RYQ09DZXJXWTRYcC1KdU9DRjRWc00xeG8zbGQxVm9jVndaVWMwQ1ExYW8xd0VuMWpHVU8tbnNROTdFUXBSemgyZWpndlhhU0J0QS16NHl6REhoNVlOZjNzOFdUZU1IaHc0djNUM04wUkQ0elNodw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTCT (NASDAQ) insider sales: 50,162 shares in June; option exercise 07/06/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPeHYtM2xFNThnYmh2blVFM2V4VHdhbmZVQzgwYVY3YzJJcUlETnRsNmoydGlyWE1tNm1FeFNIbjNMSHo5RW9wVG5JMFNmNXpnNGlLSHMyOXBLazQ4VV80TG5OTGtqeXBaNVVfRjNrTElVN0szNTZSUVN3bmxJWHZyZ0tjUjg5amM4SG11b2N0bmFBd2ladF9MaXhFTjB1dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate sale notice \u2014 PTCT (NASDAQ: PTCT) files to sell 8,130 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNUUVUS2pCOU8tUTcxRkdRLVdTVGlzOVJvYl9lemNyV1RMa3JLZmF1eENyNnhjemx1WmFKaUQ1WDZoQnp1QlpjSktkbEpFR2M1eTA2eUR3cDVyd1VnVDZQRTVCbl9qTTIxYy1XSkw5VHFGb002ODdVZFVSN0o0S3BZX3I3dDBXVW9ITExHR0wwX0pHYmV3bDc2V1BzQ25SZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ptc therapeutics chief technical ops officer sells $1.92m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQdTFrSlptMHJqOFZ2VTRYR01FNkcxSTJyenNxczA1TnlWaU1Gb1J3U3NKaHduOUJZZ1FydDNpeVhNUFpDUGE2VnFfb1hyVGF3Y25MSklWeXl3VEdYaldRbW5jR1F1ekVGZTRTNkRtSzdvMXpxZXhmUmxKNU9hOWhoYTA3akwyU2pFczdMSUFXQ1YtOVdhQXpyU2pfT3g5bFNLT2wtWFBuZXZJcXg4TkxNcmgybElVcXJNY25paEFFY0hBc3RPLWVqbQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Prognosis For PTC Therapeutics (NASDAQ:PTCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOd3RSUWlMLWR5ajlDazNHWk1OUWN2NzgwUHNHeFZiQWhuclBudXctcG5ObGVTTjZURldscTVNQTUzZlBWNEJ1YUFMMmZxUjNzbWI5eFI1RHYwSXRJZWNSUExkUm1uSThQdU1wZUNPNlk1RU5jdUgxYjJzWHJiaWdjNw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNY2N4MjNzVklicEN3bDJEQ1k0ZjR6cWoyeXpfajdPZjBBYzkzWm9VSWJCQ3ROLXR1U3lvYWhBU3ZZMlcwS1pkdlNTRzJDd0pVUC1QSHZjalNSMTUyTUwxckd2M0o5ejgwQlhraWtrNEgzaXVsQkR5S0Z3aDR2czZqOFd1MWhkdndCb2w5UDRNVzZTNTVsVUNLVlJR?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics plans $500M notes to refinance 2026 debt, buy stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNazN0aVFCUldwS2EwVkwtWHdVeXZIN1l5NTRvcWJ0WVlwQ0M5YndSckxOX2lmcGR4NlNodF91N3FhVkZ1cjJ0emxQdkhxcTh6bXJTWkxGMDRYSzRlNXotYnkwd3hJMDFFR1dHTlZQRk1PRWZSTHFVRUZWbG5mMVJIQzRpMnRhOGNYZ20zRjlmN2NHWGp1cS05SEZNQjYwUWdqNkl4SjR5UFVZY3RFTmZTVW9tc1czS3cxeXJWMg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) CBO sells shares under 10b5-1 trading plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOLU1SY0VLNVRSQURhcWZuXzk0dTZxMmdCck5JSFVvZ2pYZlNyTGdEVnpRRm9wd0dxY3VpQ2tXeFlFU1RvRElYMFJaREVyYmYzRVlUZzlkR0tBd01TbnVhSE91bThKSnZBb05qNmhxODBMU0pmczV5TFB5RjNOODh3blU0cUx6SVAyZVpya19LZEhEWDhvNkw4cGk4YWJaekpaa19DUFFEeFVXN2xBS2ZjVGJQekc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PTCT (NASDAQ: PTCT) director sells shares; restricted stock vests", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPekM3dzNPNENDamdOOGYzRWNqOFZsOEFNV0o5Wm1RTm4wTjlDcTZfdkNPUzhlVzBRaVBvNTNzWDQ1THpEN3NoVXBmWDRRUW1RQ3B2dXN4M0pUVmc1MU1vWVhmaS1PVkJwX2ZGblU1SnZtaHBTak5BeE55eGVyVDBaT3pOYWJzYkMtQ0MtLWd0TTR0RDNaV3ZtbkphSE1NZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PTC Therapeutics (PTCT) Huge Q1 Profitability Spike Tests Bullish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTG0yWGphblFtSkJMREVscFVEVEtMWW10eV9aeDRiaXYyc3hMeFhlcmNtT0JaTFBWdDBCQ2VBQUJQZHgzSkxmenNQQzY1OW12RUZNbjZRMTVISGNqdVBUNTYxcTFzenRJVVQ2QXU4TEJoZUxFZC0wLWJlVXo0blM0RExoR2wwVHRhLUhhcWtDa3hCc2k1Y1U5M010VFk2SmhaOFg1d3BpMnA5QjJ0eGRCdXhoakxEUVJfeE9YbzNlYWJzZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics Stock To $84?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNZlMwZlMyazlleDZ2RkhxR0FENkdsckk3MjE3bW9Tc2pTTjFoMGttSHhsWm9mVVppbU12N21SRHgzMVFsVy16ZWNWQVZZWDZEWm9DS2htSW1IOUxOVHZhS0NuUG5rdm1WOGpVV2FOaGt1WVZidExKZ3BuaFZMN0pTekwtSnQxZjhzbWJOaDZaZXh6dG8?oc=5", "source_name": "Trefis", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PTC Therapeutics (PTCT) Pricing Reflect Recent Pipeline Progress And Volatile Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOcmhULXlRX201YmUtamVXckdSdTEyempGaGVBblpabV9wNEJhREZYOVV4NUdlX2lQYUJZSVptUElINUYyVnptWnpDNjVxZEdSbk92eDlqNHJwQ1BTODM5LXhENUFReXkyYno3dWd5YXRUSEpRc0hEaW56ZHFQRDFtUlREbFNnaHNERHl2OGdsYUg4elJIcl9yQkQtWFZHZUhJWnNOQUFNNWliYVVqY0JYLXQ3M3FKcEVkQkpmTHNLU0IwRVZWbUlYS0NKTlJQWXFMNWtXMTc1Q1ZpaTJub093ZUotUFfSAeoBQVVfeXFMUEYyX2R0YW0zaWE3bUNZSjgyRWlaUlRJdFJUeHpKampyQm92cGJfWlJxSDAwT0pFZVZQNDRqOG9NMWp0RWxtSFltcVFiVDNzNmNNaW5nME5MeFVydk5uTzFxaWktWVJoM0NncVdLbkREd1A3YWNMcGJiSG1zbXpWNHdCanNadmk4Z0k0VURUWVZOVnZJLURENHFUS3JzWER4VEtyWGJ4Yk4wclpjLUNqY0t2MVl0RFM0WVZRdll4eGJqWDZ3VDJQTV9SSGJJemIxU2pDTXNfWjVtRHg3X2dfVU5FTm44aXRyMGp3?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PTC Therapeutics: Sephience As A Major Growth Driver (NASDAQ:PTCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPVHRieWRIQ09tN1k1d3hIWG01V0RaM3U1aGVZVXZNemx0djhJMGtXOTNSd3FhdE1iWGhacW5ubGJzc05Lek50YWs2TklLZGhHZm1FeVpaSm1FdU1aMktJNkRRU3ZJNEp6M2dUbC1YbkhRQXFRR0l2OEpmanlUcDRsRWUtSEFiOWRoWE9vd2xiWEtCdXI2R1Zr?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics Withdraws NDA Resubmission for Translarna", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQcnYzYTAyb1FTazUzMGdSNG1CZ0N4c2I5UUtYTi1ZSnowdC1fZUVuTVpCMU1EQ2l6dmhwUXYwYUpqY250WFNvQW9fV3JJMThnTk5OOXBWbEdvTGxxaUJFZXJ0U2R6TEpSLTF0ZU0zcC03M3phTjZIcVZYb3gxRW1VZmxjaU5GWGVNNk1nYmVn?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T16:22:27+00:00", "published_display": "19 Jul 2026 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNTUcwY1FLazBFeUZjY3dIN0JtNnBZcVdUNGhUX3RBTlBfYTJ2elBCeV9NRmw0d1lndzZWWlB6ZDMtYXlnY1FaZnRyYWRyYzVzQ3AzcF9Jd1dlU29xM3lyLWo4MlItVm4zNFc2dVVfM1JPY1FoRk52VWZVb2ZxcVpfcw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-19T14:58:42+00:00", "published_display": "19 Jul 2026 14:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026", "summary": "PTC Therapeutics, Inc. (PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results and provide business updates. Interested parties can access the live webcast via the Investors section of", "url": "https://www.tradingview.com/news/prnewswire:039ec3ab3880f:0-ptc-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-july-30-2026/", "source_name": "TradingView", "published_at": "2026-07-17T11:09:48", "published_display": "17 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics schedules second-quarter 2026 results webcast conference call", "summary": "PTC Therapeutics is scheduled to report its second-quarter 2026 financial results on July 30, 2026. A webcast conference call will be held on the same day at 4:30 p.m. ET, with a replay available for 30 days. This news brief was generated by Public Technologies using AI, based on", "url": "https://www.bitget.com/amp/news/detail/12560605510466", "source_name": "Bitget", "published_at": "2026-07-17T00:11:37", "published_display": "17 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 PTC Therapeutics Inc For: 16 July By Investing.com", "summary": "This article from Investing.com announces a Form 4 filing for PTC Therapeutics Inc for July 16, 2026. Form 4 filings are statements of changes in beneficial ownership of securities. The article briefly mentions other market news and includes market data and popular articles.", "url": "https://ca.investing.com/news/stock-market-news/form-4-ptc-therapeutics-inc-for-16-july-93CH-4738581", "source_name": "Investing.com Canada", "published_at": "2026-07-16T21:36:47", "published_display": "16 Jul 2026 21:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes", "summary": "PTC Therapeutics' CFO, Pierre Gravier, automatically sold 3,494 shares of common stock at $80.35 per share on July 14, 2026. This transaction was executed to fulfill tax withholding obligations tied to the vesting of 6,500 RSUs. After this sale, Gravier directly holds 83,986 shar", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-8f4a340316aa.html", "source_name": "Stock Titan", "published_at": "2026-07-16T21:20:47", "published_display": "16 Jul 2026 21:20", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics Sets July 30 Webcast for Business Update", "summary": "PTC Therapeutics (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results and provide a business and outlook update. Investors can access the live webcast and replay on the comp", "url": "https://www.stocktitan.net/news/PTCT/ptc-therapeutics-to-report-second-quarter-2026-financial-results-on-ds2l051yn3tn.html", "source_name": "Stock Titan", "published_at": "2026-07-16T12:09:47", "published_display": "16 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities", "summary": "Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on PTC Therapeutics (PTCT) with a $95.00 price target. This follows a similar Buy rating from J.P. Morgan, though RBC Capital maintained a Hold rating. The company recently reported a quarterly revenue of $27", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PTCT-Q/pressreleases/3313427/ptc-therapeutics-ptct-gets-a-buy-from-bank-of-america-securities/", "source_name": "The Globe and Mail", "published_at": "2026-07-16T11:09:47", "published_display": "16 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and a $124 price target for PTC Therapeutics (NASDAQ:PTCT), citing a strong launch for its PKU treatment, Sephience. The firm plans to engage management to discuss Sephience's global expansion, potential FDA dialogue for votop", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-ptc-therapeutics-stock-93CH-4793382", "source_name": "Investing.com", "published_at": "2026-07-15T12:40:46", "published_display": "15 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PTC THERAPEUTICS, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPUXoxZjRYZ0hqQWhvZEdEOFdNbnItZ0prTTUyU1lnejU2Zm11OEliLWZVa0lmVFdnV2JkemM2R2t0clRseGdxZ09Xbm5ib2ZNa0d5MTlYWHNYb2RLSlRCcXhuLTF3bDlVMTVXR2dYemVLcGR6bVlBekl6ZnZxT2pOQzUyVFdzTWVuSXNWVXlSbUNyZ2JzeFhENzB5OXZ1UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T19:14:52+00:00", "published_display": "14 Jul 2026 19:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders", "summary": "PTC Therapeutics reported strong Q1 2026 earnings, exceeding analyst expectations, with an improved outlook for its rare disease therapy Sephience. This positive news, despite pre-planned insider stock sales, supports the company's investment narrative and has led to analyst upgr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptct/ptc-therapeutics/news/what-ptc-therapeutics-ptcts-q1-beat-and-sephience-outlook-sh/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-14T20:14:36", "published_display": "14 Jul 2026 20:14", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Q1 2025 earnings summary", "summary": "PTC Therapeutics (PTCT) reported strong Q1 2025 results with a revenue of $1.18 billion, largely due to a $986.2 million Novartis upfront payment. The company achieved a net income of $866.6 million, a significant improvement from a net loss in Q1 2024, and ended the quarter with", "url": "https://quartr.com/events/ptc-therapeutics-inc-ptct-q1-2025_ofWxJ52K", "source_name": "Quartr", "published_at": "2026-07-14T10:14:36", "published_display": "14 Jul 2026 10:14", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) 2024 Wells Fargo Healthcare Conference Summary", "summary": "PTC Therapeutics (PTCT) presented at the 2024 Wells Fargo Healthcare Conference, highlighting strong financial performance with raised 2024 revenue guidance to $700\u2013$750 million and $1.09 billion in cash. The company provided updates on its pipeline, including three FDA applicati", "url": "https://quartr.com/events/ptc-therapeutics-inc-ptct-2024-wells-fargo-healthcare-conference_ofWxlfNE", "source_name": "Quartr", "published_at": "2026-07-14T09:40:17", "published_display": "14 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million", "summary": "", "url": "https://finance.yahoo.com/m/4b5bf0b2-8c95-309f-b0d5-9bb28d257380/what-this-ptc-therapeutics.html", "source_name": "Motley Fool", "published_at": "2026-07-13T23:48:52+00:00", "published_display": "13 Jul 2026 23:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 PTC Therapeutics Inc For: 13 July By Investing.com", "summary": "This article announces the filing of Form 4 for PTC Therapeutics Inc. on July 13. It is a very brief news item published by Investing.com, accompanied by a general market overview and links to other news and financial tools. The core content is the notification of the Form 4 fili", "url": "https://ng.investing.com/news/stock-market-news/form-4-ptc-therapeutics-inc-for-13-july-93CH-2597678", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:30:18", "published_display": "13 Jul 2026 22:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock", "summary": "Mary L. Smith, a director at PTC Therapeutics, sold 15,834 shares of common stock totaling approximately $1.43 million on July 9, 2026, after acquiring the same number of shares through stock option exercises. The sale occurred near the stock's 52-week high, following strong perf", "url": "https://www.investing.com/news/insider-trading-news/mary-l-smith-director-at-ptc-therapeutics-sells-143m-in-stock-93CH-4789468", "source_name": "Investing.com", "published_at": "2026-07-13T21:40:47", "published_display": "13 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) officer sells 2,464 shares after option exercise", "summary": "Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics (PTCT), exercised stock options to acquire 2,464 common shares at $46.54 and simultaneously sold these shares at a weighted average of $90.25 under a pre-arranged Rule 10b5-1 plan. Following these trans", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-e04210d5c28c.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:12:45", "published_display": "13 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) director trades 15,834 shares via option exercise and sale", "summary": "Mary L. Smith, a director at PTC Therapeutics (PTCT), exercised stock options for 15,834 shares at $42.95 each and subsequently sold all 15,834 shares at $90.00 each on July 9, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in Novembe", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-b5a89ab427f6.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:12:45", "published_display": "13 Jul 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) On Russell Index Inclusion And Pipeline Optimism With Fair Value In Focus", "summary": "PTC Therapeutics (PTCT) has gained investor attention due to its inclusion in three Russell 2000 Defensive indexes, two FDA New Drug Applications under review, and a potential Phase 3 Huntington's disease program. Despite reporting a loss of US$186.7 million, the company's fair v", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptct/ptc-therapeutics/news/ptc-therapeutics-ptct-on-russell-index-inclusion-and-pipelin", "source_name": "Simply Wall Street", "published_at": "2026-07-12T21:10:48", "published_display": "12 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Q2 2024 earnings summary", "summary": "PTC Therapeutics reported Q2 2024 total revenue of $187 million, with a 24% year-over-year decline in net product revenue due to lower Translarna and Emflaza sales, but a 44% increase in Evrysdi royalty revenue. The company significantly reduced its net loss to $99.2 million and ", "url": "https://quartr.com/events/ptc-therapeutics-inc-ptct-q2-2024_ofWxlcfM", "source_name": "Quartr", "published_at": "2026-07-11T20:40:21", "published_display": "11 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "This article summarizes PTC Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Key highlights include record Q1 product revenue driven by the SEPHIENCE launch, the broad R&D pipeline with ongoing clinical trials, and the significant mar", "url": "https://quartr.com/events/ptc-therapeutics-ptct-goldman-sachs-47th-annual-global-healthcare-conference-2026_ofWxvNWq", "source_name": "Quartr", "published_at": "2026-07-11T12:39:59", "published_display": "11 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNemZ2NmJKdjA1cHZ4OG91SEVlcWpMcGdPYWdBTWdlZ0Vfb0M2UGVXYmFmaWJRNVVRNnlTbG1jS0dTa3FER3h0QTFNQmE1Yy1VYmpzZFMzOHp6UGFaSVNUSi1UbzZhcUZjcFFfRU1wQ2NFN3RRRTFldkRURDdrVlVjaWduQUFwRHlPLUx2eExtQTZySnJyU3pJ?oc=5", "source_name": "Market source", "published_at": "2026-07-11T08:16:54+00:00", "published_display": "11 Jul 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PTC Therapeutics (PTCT) A Bargain Following Its Russell 2000 Defensive Index Additions?", "summary": "PTC Therapeutics (PTCT) has been added to three Russell 2000 Defensive indexes, which could influence investor interest. Despite strong recent share price performance and a common narrative suggesting the stock is 9.7% undervalued with a fair value of $93.93, valuation based on t", "url": "https://uk.finance.yahoo.com/news/ptc-therapeutics-ptct-bargain-following-231110876.html", "source_name": "Market source", "published_at": "2026-07-11T08:39:59", "published_display": "11 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics Drops 5.5% Amid Sector-Wide Selling", "summary": "PTC Therapeutics saw its share price drop by 5.5% on Friday, closing at $84.65, as part of a broader selloff in the biotechnology sector. The decline was largely attributed to sector-wide pressure rather than any company-specific news, with several peer companies experiencing sim", "url": "https://news.alphastreet.com/ptc-therapeutics-drops-5-5-amid-sector-wide-selling/amp/", "source_name": "AlphaStreet", "published_at": "2026-07-11T08:39:59", "published_display": "11 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTCT (NASDAQ: PTCT) affiliate sale notice \u2014 Form 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQNzR3QnYzZEhWUUY0dklNV3JvQjVtdXBXanlEelFyRVQwcDhBbDI3VGdTelRKYkliSFltczAxNjJQRTh5bmZBNnRuMWZMNWVSWmMxOU5hSGlYZC0xemU5TEwySlJTb0ttTFJ6RWtlWGNTd0VKdHdvelVZdExzZ2ZMN0NQUEw3ckRDc1ozRXVFbGNvZVI2RFJDYjc2RFhqQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:12:19+00:00", "published_display": "09 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 PTC Therapeutics Inc For: 8 July By Investing.com", "summary": "This article reports on a Form 4 filing for PTC Therapeutics Inc for July 8th. Form 4 filings disclose changes in beneficial ownership of company stock by insiders. The brief mention indicates an official financial transaction or holding update related to the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-ptc-therapeutics-inc-for-8-july-93CH-2591937", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T20:10:37", "published_display": "09 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Responsive Playbooks and the PTCT Inflection", "summary": "This article analyzes PTC Therapeutics Inc. (NASDAQ: PTCT), highlighting a strong sentiment across all horizons supporting an overweight bias. The analysis, generated by AI models, provides three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) ", "url": "https://news.stocktradersdaily.com/news_release/78/Responsive_Playbooks_and_the_PTCT_Inflection_070926125402_1783616042.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T13:19:04", "published_display": "09 Jul 2026 13:19", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics(PTCT.US) Officer Sells US$4.09 Million in Common Stock", "summary": "A PTC Therapeutics officer recently sold 150,000 shares of common stock for a total of $4.09 million. The transaction was disclosed through a Form 4 filing with the SEC.", "url": "https://www.moomoo.com/news/post/72670648/ptc-therapeutics-ptctus-officer-sells-us-4-09-million-in", "source_name": "Moomoo", "published_at": "2026-07-08T22:19:04", "published_display": "08 Jul 2026 22:19", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics\u2019 Mark Boulding, exec VP, sells $432,117 in stock", "summary": "Mark Elliott Boulding, Executive VP and CLO at PTC Therapeutics, Inc., sold 5,079 shares of common stock for $432,117 on July 6, 2026, under a pre-arranged trading plan. Concurrently, he acquired 5,079 shares by exercising stock options for $220,242, increasing his direct holding", "url": "https://www.investing.com/news/insider-trading-news/ptc-therapeutics-mark-boulding-exec-vp-sells-432117-in-stock-93CH-4782645", "source_name": "Investing.com", "published_at": "2026-07-08T22:10:06", "published_display": "08 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ptc therapeutics tech ops chief sells $4.1m in common stock", "summary": "PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold approximately $4.1 million in common stock and acquired $1.8 million worth of stock on July 6 and 7, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. The sales o", "url": "https://www.investing.com/news/insider-trading-news/ptc-therapeutics-tech-ops-chief-sells-41m-in-common-stock-93CH-4782646", "source_name": "Investing.com", "published_at": "2026-07-08T22:10:06", "published_display": "08 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) CLO sells shares under Rule 10b5-1 plan", "summary": "Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics (PTCT), reported selling 5,079 shares in open-market transactions and exercising options to acquire 5,039 shares on July 6, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted in Septe", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-2ccb8b73201d.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:10:06", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) officer sells shares after exercising options", "summary": "PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold 46,774 shares of common stock after exercising options. These transactions, executed on July 6-7, 2026, were performed under a pre-set Rule 10b5-1 trading plan. Almstead exercised options at prices ", "url": "https://www.stocktitan.net/sec-filings/PTCT/form-4-ptc-therapeutics-inc-insider-trading-activity-942419ef17d8.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:10:05", "published_display": "08 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ptc-therapeutics-ptct-upgraded-strong-160004329.html", "source_name": "Zacks", "published_at": "2026-07-08T16:00:04+00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-capital-adjusts-ptc-therapeutics-112618060.html", "source_name": "MT Newswires", "published_at": "2026-07-07T11:26:18+00:00", "published_display": "07 Jul 2026 11:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTCT (NASDAQ) affiliate plans option exercise; director sold 10,522 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNdkFxelhYS3JzcTNTbERyb21MMS1QQ1huTDlDLVJnOVZoMlZ5RjdrV3RYQ09DZXJXWTRYcC1KdU9DRjRWc00xeG8zbGQxVm9jVndaVWMwQ1ExYW8xd0VuMWpHVU8tbnNROTdFUXBSemgyZWpndlhhU0J0QS16NHl6REhoNVlOZjNzOFdUZU1IaHc0djNUM04wUkQ0elNodw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTCT (NASDAQ) insider sales: 50,162 shares in June; option exercise 07/06/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPeHYtM2xFNThnYmh2blVFM2V4VHdhbmZVQzgwYVY3YzJJcUlETnRsNmoydGlyWE1tNm1FeFNIbjNMSHo5RW9wVG5JMFNmNXpnNGlLSHMyOXBLazQ4VV80TG5OTGtqeXBaNVVfRjNrTElVN0szNTZSUVN3bmxJWHZyZ0tjUjg5amM4SG11b2N0bmFBd2ladF9MaXhFTjB1dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate sale notice \u2014 PTCT (NASDAQ: PTCT) files to sell 8,130 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNUUVUS2pCOU8tUTcxRkdRLVdTVGlzOVJvYl9lemNyV1RMa3JLZmF1eENyNnhjemx1WmFKaUQ1WDZoQnp1QlpjSktkbEpFR2M1eTA2eUR3cDVyd1VnVDZQRTVCbl9qTTIxYy1XSkw5VHFGb002ODdVZFVSN0o0S3BZX3I3dDBXVW9ITExHR0wwX0pHYmV3bDc2V1BzQ25SZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ptc therapeutics chief technical ops officer sells $1.92m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQdTFrSlptMHJqOFZ2VTRYR01FNkcxSTJyenNxczA1TnlWaU1Gb1J3U3NKaHduOUJZZ1FydDNpeVhNUFpDUGE2VnFfb1hyVGF3Y25MSklWeXl3VEdYaldRbW5jR1F1ekVGZTRTNkRtSzdvMXpxZXhmUmxKNU9hOWhoYTA3akwyU2pFczdMSUFXQ1YtOVdhQXpyU2pfT3g5bFNLT2wtWFBuZXZJcXg4TkxNcmgybElVcXJNY25paEFFY0hBc3RPLWVqbQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Prognosis For PTC Therapeutics (NASDAQ:PTCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOd3RSUWlMLWR5ajlDazNHWk1OUWN2NzgwUHNHeFZiQWhuclBudXctcG5ObGVTTjZURldscTVNQTUzZlBWNEJ1YUFMMmZxUjNzbWI5eFI1RHYwSXRJZWNSUExkUm1uSThQdU1wZUNPNlk1RU5jdUgxYjJzWHJiaWdjNw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNY2N4MjNzVklicEN3bDJEQ1k0ZjR6cWoyeXpfajdPZjBBYzkzWm9VSWJCQ3ROLXR1U3lvYWhBU3ZZMlcwS1pkdlNTRzJDd0pVUC1QSHZjalNSMTUyTUwxckd2M0o5ejgwQlhraWtrNEgzaXVsQkR5S0Z3aDR2czZqOFd1MWhkdndCb2w5UDRNVzZTNTVsVUNLVlJR?oc=5", "source_name": "Market source", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics plans $500M notes to refinance 2026 debt, buy stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNazN0aVFCUldwS2EwVkwtWHdVeXZIN1l5NTRvcWJ0WVlwQ0M5YndSckxOX2lmcGR4NlNodF91N3FhVkZ1cjJ0emxQdkhxcTh6bXJTWkxGMDRYSzRlNXotYnkwd3hJMDFFR1dHTlZQRk1PRWZSTHFVRUZWbG5mMVJIQzRpMnRhOGNYZ20zRjlmN2NHWGp1cS05SEZNQjYwUWdqNkl4SjR5UFVZY3RFTmZTVW9tc1czS3cxeXJWMg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) CBO sells shares under 10b5-1 trading plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOLU1SY0VLNVRSQURhcWZuXzk0dTZxMmdCck5JSFVvZ2pYZlNyTGdEVnpRRm9wd0dxY3VpQ2tXeFlFU1RvRElYMFJaREVyYmYzRVlUZzlkR0tBd01TbnVhSE91bThKSnZBb05qNmhxODBMU0pmczV5TFB5RjNOODh3blU0cUx6SVAyZVpya19LZEhEWDhvNkw4cGk4YWJaekpaa19DUFFEeFVXN2xBS2ZjVGJQekc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTCT (NASDAQ: PTCT) director sells shares; restricted stock vests", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPekM3dzNPNENDamdOOGYzRWNqOFZsOEFNV0o5Wm1RTm4wTjlDcTZfdkNPUzhlVzBRaVBvNTNzWDQ1THpEN3NoVXBmWDRRUW1RQ3B2dXN4M0pUVmc1MU1vWVhmaS1PVkJwX2ZGblU1SnZtaHBTak5BeE55eGVyVDBaT3pOYWJzYkMtQ0MtLWd0TTR0RDNaV3ZtbkphSE1NZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics (PTCT) Huge Q1 Profitability Spike Tests Bullish Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTG0yWGphblFtSkJMREVscFVEVEtMWW10eV9aeDRiaXYyc3hMeFhlcmNtT0JaTFBWdDBCQ2VBQUJQZHgzSkxmenNQQzY1OW12RUZNbjZRMTVISGNqdVBUNTYxcTFzenRJVVQ2QXU4TEJoZUxFZC0wLWJlVXo0blM0RExoR2wwVHRhLUhhcWtDa3hCc2k1Y1U5M010VFk2SmhaOFg1d3BpMnA5QjJ0eGRCdXhoakxEUVJfeE9YbzNlYWJzZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics Stock To $84?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNZlMwZlMyazlleDZ2RkhxR0FENkdsckk3MjE3bW9Tc2pTTjFoMGttSHhsWm9mVVppbU12N21SRHgzMVFsVy16ZWNWQVZZWDZEWm9DS2htSW1IOUxOVHZhS0NuUG5rdm1WOGpVV2FOaGt1WVZidExKZ3BuaFZMN0pTekwtSnQxZjhzbWJOaDZaZXh6dG8?oc=5", "source_name": "Trefis", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is PTC Therapeutics (PTCT) Pricing Reflect Recent Pipeline Progress And Volatile Share Performance", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics: Sephience As A Major Growth Driver (NASDAQ:PTCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPVHRieWRIQ09tN1k1d3hIWG01V0RaM3U1aGVZVXZNemx0djhJMGtXOTNSd3FhdE1iWGhacW5ubGJzc05Lek50YWs2TklLZGhHZm1FeVpaSm1FdU1aMktJNkRRU3ZJNEp6M2dUbC1YbkhRQXFRR0l2OEpmanlUcDRsRWUtSEFiOWRoWE9vd2xiWEtCdXI2R1Zr?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTC Therapeutics Withdraws NDA Resubmission for Translarna", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQcnYzYTAyb1FTazUzMGdSNG1CZ0N4c2I5UUtYTi1ZSnowdC1fZUVuTVpCMU1EQ2l6dmhwUXYwYUpqY250WFNvQW9fV3JJMThnTk5OOXBWbEdvTGxxaUJFZXJ0U2R6TEpSLTF0ZU0zcC03M3phTjZIcVZYb3gxRW1VZmxjaU5GWGVNNk1nYmVn?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 57, "sentiment_summary": {"positive": 16, "negative": 4, "neutral": 37, "score": 55, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 19.75, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.9, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 78.59, "latest_week": "2026-07-17", "one_week_move": -7.4, "four_week_move": -0.5, "twelve_week_move": 15.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.228109, "market_dynamics_buy_signal": false, "relative_strength": 2.771425, "fair_value_gap": 65.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.4159, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.4% over one week, -0.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 9}, {"label": "simplywall.st", "count": 5}, {"label": "Investing.com", "count": 5}, {"label": "Quartr", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-7.4% over one week, -0.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?"}], "updated_at": "2026-07-19T17:52:17.957023+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}